SWOG Selects Sequenta’s LymphoSIGHT™ Platform for Use in 180-Patient Mantle Cell Lymphoma Clinical Trial

August 6, 2012 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

SAN FRANCISCO--(BUSINESS WIRE)--Sequenta, Inc. announced today that SWOG has selected Sequenta’s LymphoSIGHT™ platform for the measurement of Minimal Residual Disease (MRD) in a clinical trial.

Twitter
LinkedIn
Facebook
Email
Print

Alliances